PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Phenotype | C0020598|hypoglycemia |
| Sentences | 3 |
| PubMedID- 23761972 | The rationale for using ohas such as sitagliptin is to improve glucose control, thereby reducing the risk of microvascular disease without inducing hypoglycemia or weight gain in patients with type 2 diabetes. |
| PubMedID- 26370882 | Background: to investigate whether a history of prior cardiovascular disease (cvd) is associated with severe hypoglycemia (sh) in patients with type 2 diabetes. |
| PubMedID- 24465132 | Where it remains available, pioglitazone can be considered as monotherapy in patients who cannot tolerate or receive metformin when their baseline a1c is roughly 1.5% or less above their goal, in patients at significant risk for repercussions from hypoglycemia (eg, those with established cardiovascular disease), and in patients where insulin resistance is strongly suspected as a significant contributor to hyperglycemia (eg, those with signs of metabolic syndrome).61 it can be used safely in patients with significant renal impairment if that were the contraindication for metformin use. |
Page: 1